Dendreon retreats after competitor reports positive trial results

Posted on June 4, 2012 by admin

Dendreon (DNDN) is sinking after Johnson & Johnson (JNJ) reported yesterday that its Zytiga prostate treatment significantly improved survival rates in certain prostate cancer patients. Dendreon has its …

Continue Reading
Source : http://feeds.finance.yahoo.com/rss/2.0/sector-healthcare?region=US&lang=en-US
This entry was posted in Healthcare. Bookmark the permalink.

Leave a Reply